• Title/Summary/Keyword: Pet imaging

Search Result 666, Processing Time 0.027 seconds

Clinical Application of $^{18}F-FDG$ PET in Malignant Melanoma (악성 흑색종에서 $^{18}F-FDG$ PET의 임상 이용)

  • Yoon, Joon-Kee
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.42 no.sup1
    • /
    • pp.140-148
    • /
    • 2008
  • $^{18}F-FDG$ PET showed a high sensitivity and specificity in the initial staging of malignant melanoma, and it also predicted the prognosis correctly. In addition, it had a higher sensitivity and specificity in the detection of recurrence and restaging than conventional imaging modalities. Meanwhile, there's less clinical evidence to support the use of $^{18}F-FDG$ PET in the response evaluation for chemotherapy and the diagnosis/differential diagnosis of malignant melanoma.

Effect of Gd-based MR contrast agents on CT attenuation of PET/CT for quantitative PET-MRI study

  • Ko, In OK;Park, Ji Ae;Lee, Won Ho;Lim, Sang Moo;Kim, Kyeong Min
    • Journal of Radiopharmaceuticals and Molecular Probes
    • /
    • v.1 no.2
    • /
    • pp.130-136
    • /
    • 2015
  • We evaluate the influence of MR contrast agent on positron emission tomography (PET) image using phantom, animal and human studies. Phantom consisted of 15 solutions with the mixture of various concentrations of Gd-based MR contrast agent and fixed activity of [$^{18}F$]FDG. Animal study was performed using rabbit and two kinds of MR contrast agents. After injecting contrast agent, CT or MRI scanning was performed at 1, 2, 5, 10, and 20 minutes. PET image was obtained using clinical PET/CT scan, and attenuation correction was performed using the all CT images. The values of HU, PET activity and MRI intensity were obtained from ROIs in each phantom and organ regions. In clinical study, patients (n=20) with breast cancer underwent sequential acquisitions of early [$^{18}F$]FDG PET/CT, MRI and delayed PET/CT. In phantom study, as the concentration increased, the CT attenuation and PET activity also increased. However, there was no relationship between the PET activity and the concentration in the clinical dose range of contrast agent. In animal study, change of PET activity was not significant at all time point of CT scan both MR contrast agents. There was no significant change of HU between early and delayed CT, except for kidney. Early and delayed SUV in tumor and liver showed significant increase and decrease, respectively (P<0.05). Under the condition of most clinical study (< 0.2 mM), MR contrast agent did not influence on PET image quantitation.

Application of PET in Brain Tumor (뇌종양에서 PET의 임상이용)

  • Chung, June-Key
    • The Korean Journal of Nuclear Medicine
    • /
    • v.36 no.1
    • /
    • pp.19-27
    • /
    • 2002
  • The annual incidence of primary brain tumors is 7-19 cases per 100,000 people. The unique capacity of visualizing biochemical processes allows PET to determine functional metabolic activities of the brain tumors. Like other malignant tumors, F-18 FDG has been used commonly in the imaging of brain tumors. FDG PET is valuable in grading malignancy, predicting prognosis, monitoring treatment, differentiating tumor recurrence from radiation necrosis, and detecting primary lesion in metastatric brain tumors. Among amino acids labeled with positron emitters, C-11 methionine is used clinically. Tumor delineation is much better with methionine PET than with FDG PET. Low grade gliomas, in particular, are better evaluated with methionine than with FDG. PET opens another dimension in brain tumor imaging. PET imaging has clearly entered the clinical area with a profound impact on patient care in many indications.

Clinical Applications of $^{18}F$-FDG PET/CT in Malignant Bone and Soft Tissue Tumors (악성 골 및 연부조직 종양에서 $^{18}F$-FDG PET/CT의 임상적 적용)

  • Shin, Duk-Seop
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.14 no.2
    • /
    • pp.86-94
    • /
    • 2008
  • $^{18}F$-FDG PET/CT has led to advancement in diagnostic imaging, providing correlation of both physiology and anatomic information, and to new and innovative ways to utilize PET/CT imaging for the evaluation of musculoskeletal tumors. Recently, the most widely utilized musculoskeletal application of PET/CT imaging is for the detection and characterization of bone metastases, staging and restaging of primary malignant bone tumors and soft tissue sarcomas. And it is also useful in evaluating response to therapy for malignant musculoskeletal tumors and in detecting local recurrences or distant metastases during follow up. The future likely holds even more unique and potentially quite useful applications of PET/CT imaging for primary bone and soft tissue tumors. This article will review the useful applications of $^{18}F$-FDG PET/CT imaging for evaluating musculoskeletal tumors.

  • PDF

[ $^{18}F-FDG$ ] PET/CT in POEMS Syndrome (POEMS syndrome에서의 $^{18}F-FDG$ PET/CT 소견)

  • An, Young-Sil;Yoon, Joon-Kee;Hong, Seon-Pyo;Joh, Chul-Woo;Yoon, Seok-Nam
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.41 no.1
    • /
    • pp.66-67
    • /
    • 2007
  • POEMS syndrome is a rare disorder, also known as Crow-Fukase, PEP or Takatsuki syndrome. The acronym, POEMS, represents polyneuropathy, organomegaly, endocrinopathy, M protein and skin change. However, there are associated features not included in the acronym such as sclerotic bone lesions, Castleman disease, papilledema, thromobocytosis, peripheral edema, ascites, effusion, polycythemia, fatigue and clubbing. In most cases, osseous lesions in POEMS syndrome present as an isolated sclerotic deposit and that reveal as osteosclerotic myeloma. Several cases of $^{18}F-FDG$ PET in multiple myeloma involvements were reported, but there was no previous literature that reported FDG PET findings in POEMS syndrome. We describe here a 66-year-old patient with POEMS syndrome who underwent $^{18}F-FDG$ PET/CT image.

Molecular Imaging in the Age of Genomic Medicine

  • Byun, Jong-Hoe
    • Genomics & Informatics
    • /
    • v.5 no.2
    • /
    • pp.46-55
    • /
    • 2007
  • The convergence of molecular and genetic disciplines with non-invasive imaging technologies has provided an opportunity for earlier detection of disease processes which begin with molecular and cellular abnormalities. This emerging field, known as molecular imaging, is a relatively new discipline that has been rapidly developed over the past decade. It endeavors to construct a visual representation, characterization, and quantification of biological processes at the molecular and cellular level within living organisms. One of the goals of molecular imaging is to translate our expanding knowledge of molecular biology and genomic sciences into good patient care. The practice of molecular imaging is still largely experimental, and only limited clinical success has been achieved. However, it is anticipated that molecular imaging will move increasingly out of the research laboratory and into the clinic over the next decade. Non-invasive in vivo molecular imaging makes use of nuclear, magnetic resonance, and in vivo optical imaging systems. Recently, an interest in Positron Emission Tomography (PET) has been revived, and along with optical imaging systems PET is assuming new, important roles in molecular genetic imaging studies. Current PET molecular imaging strategies mostly rely on the detection of probe accumulation directly related to the physiology or the level of reporter gene expression. PET imaging of both endogenous and exogenous gene expression can be achieved in animals using reporter constructs and radio-labeled probes. As increasing numbers of genetic markers become available for imaging targets, it is anticipated that a better understanding of genomics will contribute to the advancement of the molecular genetic imaging field. In this report, the principles of non-invasive molecular genetic imaging, its applications and future directions are discussed.

Myocardial Perfusion PET (심근관류 PET)

  • Cho, Ihn-Ho;Kong, Eun-Jung
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.43 no.3
    • /
    • pp.207-214
    • /
    • 2009
  • Positron emission tomogrpahy (PET) represents the most advanced scintigraphic imaging technology. With the increase in availability of PET, the clinical use of PET has grown in medical fields. This can be employed for cardiovascular research as well as for clinical applications in patients with various cardiovascular disease. PET allows non-invasive functional assessment of myocardial perfusion, substrate metabolism and cardiac innervation and receptors as well as gene expression in vivo. PET is regarded as the gold standard for the detection of myocardial viability, and it is the only method available for the quantitative assessment of myocardial blood flow. This review focuses on the clinical applications of myocardial perfusion PET in coronary artery disease.

Oral cancer diagnosed using PET/CT: A case report (PET/CT를 이용하여 진단한 구강암의 증례)

  • Kim Young-Hee;Yang Byoung-Eun;Cho Young-Min;Kim Seong-Gon
    • Imaging Science in Dentistry
    • /
    • v.36 no.2
    • /
    • pp.111-116
    • /
    • 2006
  • PET/CT is a new imaging technology that combines high-quality Positron Emission Tomography (PET) and Computed Tomography (CT). This imaging provides simultaneous anatomical and metabolic information. Therefore PET/CT is useful diagnostic modality for early detection of malignant tumor, accurate staging, decision on therapeutic plan, monitoring response to therapy and rapid detection of recurrence. We report oral and maxillofacial cancers diagnosed by using PET/CT and the usefulness of PET/CT in the evaluation of postoperative recurrence.

  • PDF

Multimodality and Application Software (다중영상기기의 응용 소프트웨어)

  • Im, Ki-Chun
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.42 no.2
    • /
    • pp.153-163
    • /
    • 2008
  • Medical imaging modalities to image either anatomical structure or functional processes have developed along somewhat independent paths. Functional images with single photon emission computed tomography (SPECT) and positron emission tomography (PET) are playing an increasingly important role in the diagnosis and staging of malignant disease, image-guided therapy planning, and treatment monitoring. SPECT and PET complement the more conventional anatomic imaging modalities of computed tomography (CT) and magnetic resonance (MR) imaging. When the functional imaging modality was combined with the anatomic imaging modality, the multimodality can help both identify and localize functional abnormalities. Combining PET with a high-resolution anatomical imaging modality such as CT can resolve the localization issue as long as the images from the two modalities are accurately coregistered. Software-based registration techniques have difficulty accounting for differences in patient positioning and involuntary movement of internal organs, often necessitating labor-intensive nonlinear mapping that may not converge to a satisfactory result. These challenges have recently been addressed by the introduction of the combined PET/CT scanner and SPECT/CT scanner, a hardware-oriented approach to image fusion. Combined PET/CT and SPECT/CT devices are playing an increasingly important role in the diagnosis and staging of human disease. The paper will review the development of multi modality instrumentations for clinical use from conception to present-day technology and the application software.